|
|
 Previous Article | Table of Contents | Next Article 
A gp130 Interleukin-6 Transducer-Dependent SCID Model of
Human Multiple Myeloma
Cosette Rebouissou,
John Wijdenes,
Patrick Autissier,
Karin Tarte,
Valerie Costes,
Janny Liautard,
Jean-Francois Rossi,
Jean Brochier, and
Bernard Klein
From the Institute for Molecular Genetics, CNRS, Montpellier, France;
the Diaclone, Besançon, France; INSERM U475, Montpellier, France;
and the Service des Maladies du Sang B, CHU Montpellier, Hôpital
Lapeyronie, Montpellier, France.
Agonist antihuman gp130 transducer monoclonal antibodies (MoAbs)
were used in SCID mice to grow myeloma cells whose survival and
proliferation is dependent on gp130 transducer activation. The agonist
anti-gp130 MoAbs neither bound to murine gp130 nor activated murine
cells and, as a consequence, did not induce interleukin-6 (IL-6)-related toxicities in mice. They have a 2-week half-life in
vivo when injected in the peritoneum. The agonist antibodies made
possible the in vivo growth of exogenous IL-6-dependent human myeloma
cells as well as that of freshly explanted myeloma cells from 1 patient
with secondary plasma cell leukemia. Tumors occurred 4 to 10 weeks
after myeloma cell graft and weighed 3 to 5 g. They grew as solid
tumors in the peritoneal cavity and metastasized to the different
peritoneal organs: liver, pancreas, spleen, and intestine. Tumoral
cells were detected in blood and bone marrow of mice grafted with the
XG-2 myeloma cells. Tumoral cells grown in SCID mice had kept the
phenotypic characteristics of the original tumoral cells and their in
vitro growth required the presence of IL-6 or agonist anti-gp130 MoAbs.
Myeloma cells from 4 patients with medullary involvement persisted for
more than 1 year as judged by detectable circulating human Ig. However,
no tumors were detected, suggesting a long-term survival of human
myeloma cells without major proliferation. These observations
paralleled those made in in vitro cultures as well as the tumor growth
pattern in these patients. This gp130 transducer-dependent SCID model
of multiple myeloma should be useful to study various therapeutical
approaches in multiple myeloma in vivo.
Blood, Vol. 91 No. 12 (June 15), 1998:
pp. 4727-4737
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
J. Moreaux, D. Hose, M. Jourdan, T. Reme, M. Hundemer, M. Moos, N. Robert, P. Moine, J. De Vos, H. Goldschmidt, et al.
TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines
Haematologica,
June 1, 2007;
92(6):
803 - 811.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mahtouk, D. Hose, P. Raynaud, M. Hundemer, M. Jourdan, E. Jourdan, V. Pantesco, M. Baudard, J. De Vos, M. Larroque, et al.
Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma
Blood,
June 1, 2007;
109(11):
4914 - 4923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Condomines, D. Hose, P. Raynaud, M. Hundemer, J. De Vos, M. Baudard, T. Moehler, V. Pantesco, M. Moos, J.-F. Schved, et al.
Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis
J. Immunol.,
March 1, 2007;
178(5):
3307 - 3315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Moreaux, D. Hose, T. Reme, E. Jourdan, M. Hundemer, E. Legouffe, P. Moine, P. Bourin, M. Moos, J. Corre, et al.
CD200 is a new prognostic factor in multiple myeloma
Blood,
December 15, 2006;
108(13):
4194 - 4197.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Matsui, C. A. Huff, Q. Wang, M. T. Malehorn, J. Barber, Y. Tanhehco, B. D. Smith, C. I. Civin, and R. J. Jones
Characterization of clonogenic multiple myeloma cells
Blood,
March 15, 2004;
103(6):
2332 - 2336.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Mahtouk, M. Jourdan, J. De Vos, C. Hertogh, G. Fiol, E. Jourdan, J.-F. Rossi, and B. Klein
An inhibitor of the EGF receptor family blocks myeloma cell growth factor activity of HB-EGF and potentiates dexamethasone or anti-IL-6 antibody-induced apoptosis
Blood,
March 1, 2004;
103(5):
1829 - 1837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tarte, J. De Vos, T. Thykjaer, F. Zhan, G. Fiol, V. Costes, T. Reme, E. Legouffe, J.-F. Rossi, J. Shaughnessy Jr, et al.
Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts
Blood,
July 30, 2002;
100(4):
1113 - 1122.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. De Vos, G. Couderc, K. Tarte, M. Jourdan, G. Requirand, M.-C. Delteil, J.-F. Rossi, N. Mechti, and B. Klein
Identifying intercellular signaling genes expressed in malignant plasma cells by using complementary DNA arrays
Blood,
August 1, 2001;
98(3):
771 - 780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. JONES, S. HORIUCHI, N. TOPLEY, N. YAMAMOTO, and G. M. FULLER
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
FASEB J,
January 1, 2001;
15(1):
43 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Tarte, X.-G. Zhang, E. Legouffe, C. Hertog, M. Mehtali, J.-F. Rossi, and B. Klein
Induced Expression of B7-1 on Myeloma Cells Following Retroviral Gene Transfer Results in Tumor-Specific Recognition by Cytotoxic T Cells
J. Immunol.,
July 1, 1999;
163(1):
514 - 524.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. H. Wang, X. Y. Yang, K. Mihalic, W. Xiao, D. Li, and W. L. Farrar
Activation of Estrogen Receptor Blocks Interleukin-6-inducible Cell Growth of Human Multiple Myeloma Involving Molecular Cross-talk between Estrogen Receptor and STAT3 Mediated by Co-regulator PIAS3
J. Biol. Chem.,
August 17, 2001;
276(34):
31839 - 31844.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
